Ovary leiomyosarcoma

Summary

Ovary leiomyosarcoma (MONDO:0003355) is a disease and 2 clinical trials. Top therapeutic interventions include gemcitabine and trabectedin. A subtype of ovarian sarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ovary leiomyosarcoma
Mondo ID	MONDO:0003355
EFO	EFO:0006718
DOID	DOID:5263
NCIT	C5234
UMLS	C1335163
MedGen	233275
GARD	0023470
Anatomy (UBERON)	UBERON:0000992
Is cancer (heuristic)	no

Also known as: leiomyosarcoma of ovary · leiomyosarcoma of the ovary · ovarian leiomyosarcoma · ovary leiomyosarcoma

Data availability: 1 cell line.

Disease family

This is a subtype of ovarian sarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › female reproductive organ cancer › ovarian cancer › ovarian sarcoma › ovary leiomyosarcoma

Related subtypes (3): ovary rhabdomyosarcoma, ovarian angiosarcoma, liposarcoma of the ovary

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04383119	PHASE2	RECRUITING	Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma
NCT06749600	Not specified	RECRUITING	Clinical Management and Outcomes of Primary Ovarian Leiomyosarcoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
GEMCITABINE	4	1
TRABECTEDIN	4	1